Compare AMN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMN | DRUG |
|---|---|---|
| Founded | 1985 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Assisted Living Services | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.0M | 707.1M |
| IPO Year | 2001 | 2020 |
| Metric | AMN | DRUG |
|---|---|---|
| Price | $28.19 | $86.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $22.25 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 657.2K | 153.7K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.58 | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $1,988,454,000.00 | N/A |
| Revenue This Year | $17.27 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $14.97 | $23.18 |
| 52 Week High | $23.71 | $123.75 |
| Indicator | AMN | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 83.30 | 50.91 |
| Support Level | $17.76 | $72.06 |
| Resistance Level | N/A | $91.69 |
| Average True Range (ATR) | 1.19 | 4.34 |
| MACD | 0.56 | -0.63 |
| Stochastic Oscillator | 97.24 | 43.04 |
AMN Healthcare Services Inc provides healthcare workforce solutions and staffing services in the United States. Its comprehensive suite of talent solutions provides management, staffing, recruitment, language services, technology, predictive and market analytics, and related services to build and manage all or parts of the clients' healthcare workforce needs. Its reportable segments are: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. A majority of its revenue is generated from the Nurse and Allied Solutions segment, which includes the company's travel nurse staffing, labor disruption staffing, local staffing, international nurse permanent placement, and allied staffing (including revenue cycle solutions) businesses.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.